biote Corp.

Biote Corp. (Nasdaq: BTMD) is a healthcare company specializing in hormone optimization that completed its public listing through a de-SPAC merger with Haymaker Acquisition Corp. III, a blank-check vehicle sponsored by Haymaker Partners that launched its IPO in 2021. On November 29, 2021, the company submitted a Form 10-Q/A, an amended quarterly report, to the SEC under accession number 0001193125-21-342432, updating a prior periodic disclosure during the SPAC's pre-merger period. Biote operates in the bioidentical hormone replacement therapy segment of the healthcare industry, partnering with medical practitioners across the United States. To access complete filing data and deal analytics for BTMD and the broader SPAC universe, sign up for SpacDesk.